🎄✨ Season’s greetings from our team!
T
hank you to all colleagues for your dedication, teamwork, and commitment throughout the year. We’re proud of what we’ve achieved together and look forward to continuing our work in 2026.
Wishing everyone peaceful holidays and a joyful New Year! ✨🎁
🌟 Exciting times for our MOTION team!
We’re growing and evolving as we enter Year 3 — with new roles, fresh perspectives & shared dedication to advance hepatology and improve patient outcomes.
💪 Here’s to another year of teamwork & innovation!
#MOTIONTeam #LiverResearch
🎉 Congrats to Mathias Jachs, MD, PhD on completing his Habilitation at MedUni Vienna — an impressive milestone at such a young age! 👏
His lecture covered liver cirrhosis, CSPH & hepatitis B/D.
💪 We’re proud to have him on our MOTION team!
#Hepatology
🩸Next - WP6: Coagulation & Hemostasis Research
Our specialists is working to characterize rebalanced hemostasis in #ACLD & #PSVD using advanced diagnostics like #ClotPro & TM-TGA.
#Portalhypertension #coagulation #liver #Clinicaltrial
After a long summer break, we continue introducing our work packages of project MOTION.
UP next is WP5 introduced and led by
@mathiasjachs.bsky.social
🖐️
Developing prognostic #NIT models for #ACLD or #PSVD
📷More info in the video below 📷
@reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social thank you very much for sharing our experience and hosting the annual meeting!
🙌We wrapped up an amazing MOTION annual meeting! 🙌
Reflected on 2 years of growth & scientific insights, and set course for the next 2 years.
Next step: making our 3 clinical trials – and project MOTION as a whole – an outstanding success! 💫
#MotionProject #TeamScience #ClinicalTrials
👋 After a short break, we continue to introduce our WPs to you👋
Next one is MOTION WP 4 led and introduced by
@mattiasmandorfer.bsky.social
- Comparing #HVPG responses of our medication within our clinical trials to NSBBS...
🌐More info in the video below 📷🔽
💫This week we are introducing WP4 & WP5 💫
Focused on HVPG response to therapy, NIT-based prognostic models, & clinical outcomes in #ACLD/#PSVD.
🔬 A comprehensive approach to #hepatology research.
Led by @mattiasmandorfer.bsky.social & @mathiasjachs.bsky.social
📷More info in the graphic 📷
🎥 Say hi to Work Package 3 of the #MotionProject!
WP lead Dr. Georg Semmler gives a quick introduction into how we’re tackling PSVD—from molecular insights to clinical impact. 💡
Watch now & learn more about our mission in hepatology!
#WP3 #LiverResearch #PSVD #ScienceInMotion
🧬 WELCOME to WP3, In this WP we're exploring the molecular & prognostic characterization of PSVD using histology, metabolomics & RNA-seq.
The key element: the EXPOSURE trial, investigating anticoagulation with Edoxaban in PSVD patients.
#MotionProject #PSVD #WP3 #LiverResearch #ClinicalTrials
🌐 Introducing MOTION WorkPackage 2 by @reibergerthomas.bsky.social 🌐
In this particular WP the team is focusing on decompensated cirrhosis..
#liver #PortalHypertension #clinicaltrails #dACLD
🔽 Find out more in the video below 📷🔽
🧠 New paper by @LorenzBalcar shows that #spleenstiffness measurement (SSM) via transient elastography helps non-invasively stratify #portalhypertension in BCR::ABL1⁻ MPN — beyond #liver stiffness.
A step forward in risk assessment!
📊👇More info 📊👇
lnkd.in/du8-FjgE
Some of our Motion team members are currently at #EASL2025 in Amsterdam — proudly representing our deep expertise in liver research and innovation. Come say hi if you're around! 👋
#MotionTeam #EASL2025 #LiverResearch #Innovation #ProudToRepresent
#Portalhypertension Fans ⬇️
🥂🥂 OUR deputy PI
@MattiasMandorf1
.
received the "EASL Emerging Leader Awards 2025" in Amsterdam yesterday at #EALS2025
We congratulate him from the bottom of our #livers 😉 and are incredibly proud!
🌐 MOTION Work Package 2 🌐
WP2 focuses on decompensated cirrhosis. Heart of the this wp is a clinical trial led by @reibergerthomas.bsky.social investigating the potential beneficial effects of norfloxacin in this patient group.
⬇️⬇️⬇️⬇️
#liver #liverdesease #PortalHypertension #ClinicalTrial
#liver #PortalHypertension #clinicaltrails #cACLD
Introducing MOTION WP 1 - Focusing on pathophysiological mechanisms in compensated Patients with liver cirrhosis....
🌐More info in the video below 🌐 🔽🔽
💬Introducing WP1💬
This WP focuses on the classical & alternative renin-angiotensin system as a disease-driving mechanism in patients with cACLD. The heart of WP1 is a clinical trail to investigate potentially beneficial effects of telmisartan in this patient group.
🌐Fridays with the MOTION Team = science, smiles & serious vibes 😎🧪
Just something else.... :) 🌐
When top-notch research meets good energy, magic happens. Work hard, laugh harder — that’s how we roll.
#MOTIONProject #ScienceSquad #FridayFeeling #TeamworkMakesTheDreamWork
🌟 Our MOTION team is growing – so are our achievements! 🌟
While knowledge is undoubtedly necessary in a project, people form the foundation of success...
Physicians, PhDstudents, PMs, StudyNurses & DataManagers bring their unique skills & perspectives that make our MOTION project truly special
🥳🥳 Proud to announce that another VLSG member Nikolaus Pfisterer has successfully defended his #PhD at @meduniwien.ac.at
🙌🙌🙌 Congrats and let's celebrate!! 🙌🙌🙌
MEET the MOTION Team!
A team of clinical & basic researchers, assembled by @reibergerthomas.bsky.social & @mattiasmandorfer.bsky.social to conduct clinical studies & translational research on PH-driving molecular mechanisms.
Those aspiring members are divided in 8 WPs assigned to their expertise.
#PortalHypertension Fans !! #liver 👍
We are thrilled to share that our clinical trial is in full swing!
It is divided in 8 work packages and over the upcoming weeks, we’ll introduce each innovative work package, with the dedicated experts, driving this project forward.
⬇️📷More info 📷⬇️
🚀 Behind the abbreviation MOTION is a top-tier clinical research group at MedUni Vienna tackling portal hypertension – the key driver of liver disease morbidity & mortality. 🔬
⬇️ Follow for more info... ⬇️
#portalhypertension #research #clinicaltrail #liver #blueskyliver
